Systemic sclerosis is, as yet, an untreatable disase and the choice and evaluation of any modifying treatment are extremely difficult. This is because: (a) the disorder is heterogeneous and its severity and rate of progression highly variable; (b) there is a tendency towards spontaneous improvement during the later stages of the disease, particularly within the more benign and numerically larger subset; (c) the cause is unknown, its pathogenesis uncertain, and the relation between the vascular damage, immune dysfunction, and fibrosis speculative; (d) there is a paucity of objective criteria for ascertaining improvement (or deterioration) in the disease, particularly with respect to visceral change.
This review will not seek to describe the numerous ways in which systemic sclerosis has been treated nor to comment on the vast number of vitamins, alternative medicine products, hormones, and surgical procedures that have been used (most of which have been heralded with great enthusiasm only to be abandoned after critical evaluation) but to suggest a logical approach to the use of drugs in systemic sclerosis and then to discuss some recent therapeutic ventures.
Before a treatment is decided upon for any aspect of the disease the two most important tasks for the doctor are to classify the patients and to endeavour to recognise the 'at risk' population.
Subsets of systemic sclrosis (Reproduced, uith Recognition of the at risk group before the disease cascade gathers momentum is equally important. Possible helpful clues are circulating antibodies, cytokine production, and nailfold changes. Such identification allows for 'protective' therapeutic intervention. These ideas should also be extended to the earliest possible diagnosis of internal organ involvement, which again might allow for its containment. For example, fine cut (3 mm) computed tomography scans of the lungs, measurement of cytokines, growth factors and procollagen peptides in bronchoalveolar lavage fluid might, in the future, aid the recognition of lung disease, now the major cause of death in scleroderma.
No single drug or combination of drugs has proved satisfactory in the treatment of systemic sclerosis in suitably controlled prospective trials. This is perhaps understandable when one considers that concepts of systemic sclerosis are still evolving.
Obviously, development of the scleroderma lesion is complicated and entails several events that may occur simultaneously or in sequence. These almost certainly include inflammation, autoimmune attack, vascular damage, fibroblast activation by cytokines and growth factors, and interaction between different components of the extracellular matrix. There are, therefore, several different potential points of therapeutic intervention.
Although The theoretical rationale for lymphoplasmapheresis may be sounder than plasma exchange, and a preliminary report by Weiner was encouraging. 1 Considering the almost certain need to target the immune system and the nonselectivity of the immunosuppressive drugs, O'Dell et al tried total lymphoid irradiation and found it wanting with, in addition, the possible acceleration of visceral disease in the irradiated patients. 17 Targeting the immune systems more specifically is, however, still an attractive idea and the use of rabbit antithymocyte-globulin is worthy of investigation. To date only two cases have been reported,'8 but other studies are currently in hand.
Use of the antimetabolites 6-thioguanine and methotrexate has been reported in a few cases.9 20 The information is, however, too scant to provide any useful conclusions. Azathioprine has been more widely used-always, unfortunately, in uncontrolled studies8 21 To date there is obviously no general agreement on the place of these drugs. To use them to the greatest effect more information is urgently needed on the specific immune defect so that targeting can be achieved and the drugs used at the most effective stage of the diffuse disorder-one suspects this stage to be the earliest possible beginnings. These drugs should not be used for late stage, stable diffuse or limited cutaneous disease.
Drugs which target collagen synthesis, such as colchicine and D-penicillamine, have been used in the treatment of scleroderma for many years. Neither is the answer to the fibrotic deposition, but consensus opinion is that Dpenicillamine is the most useful. The drug must be used correctly to derive the maximum benefit, and the most suitable subjects for treatment are those with widespread active skin disease. Long term treatment in a dose around 500-750 mg is needed. Skin changes in the diffuse form of the disease are often rapid in the first six to 12 months and show a limited response to all known forms of treatment-Dpenicillamine included. The pace of change then usually slows down with regression occurring in many areas. D-Penicillamine should be continued throughout this whole period and the dose maintained until there is no further improvement in skin thickening. The drug may then be reduced, but low dose treatment should be maintained for many years-some recommend 10 years. 27 The patients who present after spontaneous regression of skin changes should not be treated.
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